08:00 , Feb 16, 2009 |  BC Week In Review  |  Clinical News

NGX426: Phase I data

A double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial in 20 healthy volunteers showed that 90 and 150 mg NGX426 for 5 consecutive days was well tolerated with no dose-limiting adverse events or discontinuations. TorreyPines Therapeutics...
08:00 , Dec 8, 2008 |  BC Week In Review  |  Clinical News

NGX426: Phase I data

In a double-blind Phase I trial in 18 healthy volunteers, 150 mg of NGX426 met the co-primary endpoints of significant reductions in spontaneous pain, hyperalgesia and allodynia vs. placebo. A 90 mg dose of NGX426...
07:00 , Oct 27, 2008 |  BC Week In Review  |  Clinical News

NGX426: Phase I started

TorreyPines began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate 90 or 150 mg of oral NGX426 given daily for 5 days in 20 healthy volunteers. TorreyPines Therapeutics Inc. (NASDAQ:TPTX), La Jolla, Calif.   Product:...
07:00 , Oct 9, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology ...
07:00 , Jul 7, 2008 |  BC Week In Review  |  Clinical News

Tezampanel: Additional Phase II data

Additional data from a double-blind, placebo-controlled, U.S. Phase II trial (NGX424MIG2001) in 306 patients showed that tezampanel improved the secondary endpoints of sustained headache response, absence of nausea or vomiting, absence of phonophobia and absence...
07:00 , Jun 9, 2008 |  BC Week In Review  |  Clinical News

NGX426: Phase I started

TorreyPines began a placebo-controlled, 3-way crossover, U.S. Phase I trial to compare 90 and 150 mg doses of oral NGX426 vs. placebo in 18 healthy volunteers experiencing capsaicin-induced pain. TorreyPines Therapeutics Inc. (NASDAQ:TPTX), La Jolla,...
07:00 , May 5, 2008 |  BC Week In Review  |  Company News

TorreyPines, Johns Hopkins University deal

The university granted TorreyPines exclusive rights to IP related to new uses for glutamate receptor antagonists, including the company's lead compounds tezampanel and NGX426, to treat and prevent stroke, heart attack and other conditions...
08:00 , Feb 18, 2008 |  BC Week In Review  |  Company News

TorreyPines neurology, other news

TorreyPines reduced headcount by about 10 (23%) to 33 as a result of the Feb. 28, 2008 expiration of a 2005 deal with Eisai Co. Ltd. (Tokyo:4523; Osaka:4523, Tokyo, Japan) to discover therapeutics for...
08:00 , Feb 18, 2008 |  BC Week In Review  |  Clinical News

Tezampanel: Phase II start

Next half, TorreyPines plans to start a double-blind, placebo-controlled, U.S. Phase II trial of subcutaneous tezampanel given once daily. TorreyPines Therapeutics Inc. (NASDAQ:TPTX), La Jolla, Calif.   Product: Tezampanel ( NGX424)   Business: Neurology   Molecular target: ...
08:00 , Feb 18, 2008 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 2/15 cls Adolor (NASDAQ:ADLR) Cowen Leland Gershell Upgrade Market outperform (from neutral) -5% $3.75 Gershell upgraded the stock after FDA extended the PDUFA date...